Although a combination therapy blocking both VEGF and angiopoietin‐2 is additive to reduce angiogenesis and tumor growth, it may promote even greater hypoxia than monotherapy (Koh et al, 2010; Rigamonti et al, 2014; Scholz et al, 2016). This evidence concerns the gene VEGFA and neoplasm.